Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that ureteroileal anastomosis with direct intraluminal visualization had a 4.2% stricture rate, which compares favorably to other techniques with rates between 3.5% and 11.1%.

Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.

The book explains causes and treatments for common hair loss, its psychological effects, related health risks, and emphasizes early screening and lifestyle changes.

This article discusses androgenetic alopecia as a potential early marker for benign prostatic hyperplasia but reports no new clinical findings.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

This study found that men with early-onset androgenetic alopecia had larger prostate volumes and lower urinary flow rates compared to those without the condition, suggesting a potential link between AGA and urinary symptoms.

This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.

In this study conducted at Sir Ganga Ram Teaching Hospital in Pakistan, researchers found that preoperative use of finasteride significantly reduced intraoperative blood loss and shortened hospital stay for benign prostatic hyperplasia patients undergoing bipolar TURP, compared to those not receiving finasteride.

This review discusses the potential of herbal treatments like Saw palmetto, Green tea, and Rosemary as alternatives to conventional drugs for androgenetic alopecia, noting that these herbs may inhibit the 5-alpha-reductase enzyme and reduce hair loss with fewer side effects.

This review discusses the potential of plant-based preparations for treating hair loss and reports no new clinical results; the authors highlight herbs with evidence of efficacy against alopecia.

This study suggests that early onset androgenetic alopecia in men may indicate a male PCOS equivalent, possibly leading to higher risks of metabolic and cardiovascular disorders later in life.

This study found that men with early-onset androgenetic alopecia had significantly larger prostate volumes and lower urinary flow rates compared to healthy controls, suggesting a possible link between AGA and prostate-related urinary symptoms.

In this study, five-year testosterone replacement therapy improved fasting blood sugar, HbA1c, and triglyceride levels in Japanese hypogonadal men without significantly affecting prostate-specific antigen levels.

Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.

This paper proposes a new hypothesis that androgenic hair loss may be caused by changes in scalp vasculature due to androgen effects, but reports no new experimental results.

This review explores the risk factors, associated comorbidities, and psychological impacts of early-onset androgenetic alopecia, highlighting its complexity and potential implications for treatment response and overall health.

This study reports on biofeedback treatment for dysfunctional voiding in three adult cases, providing insights into this condition when diagnosed beyond childhood.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Genetics and hormones cause hair loss; finasteride treats it safely.

This review discusses the potential benefits of flavonoid-containing botanicals, such as Panax ginseng, in reducing hair loss and promoting hair growth, but reports no new experimental results.

This study reports that prostate volume, operation time, resected tissue weight, and smoking increase risks of blood loss and fluid absorption during PK-TURP, while finasteride treatment and surgeon experience may reduce these risks.

Researchers developed a quick and sensitive way to measure finasteride in blood using a small sample size.

This systematic review of five studies found that intradermal and intramuscular botulinum toxin injections showed promising hair growth outcomes for men with androgenic alopecia, but emphasizes caution due to a lack of control groups and small sample sizes.

This study using Mendelian randomization in UK Biobank data suggests that lifelong increased free testosterone may have mixed effects, including increased bone density and prostate cancer risk, warranting well-powered trials to address uncertainties.

This Mendelian randomization study reports that lifelong increased free testosterone in males was associated with improved bone mineral density and body composition but increased risks of prostate cancer, hypertension, and several other conditions.

This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.

This study found that six weeks of finasteride therapy before TURP reduced intraoperative blood loss and improved early postoperative quality of life in patients with benign prostatic hyperplasia.

This study found that patients with BPH who received finasteride before TURP experienced reduced intraoperative blood loss and improved quality of life one month after surgery compared to those who did not.

This article discusses the potential health risks associated with long-term use of finasteride and dutasteride for prostate and hair loss treatments, suggesting risks may include non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, and other metabolic issues.

This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.